AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00305162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bolus & placebo infusion
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Study NCT00305162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules - end of infusion
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Study NCT00305162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules - as soon as possible after randomization
Description: Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
Study NCT01618968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: * Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)
Study NCT00395993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
Study NCT00395993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325 mg tablets TID on Days 0 through Day 42
Study NCT04503317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active acupuncture low level laser in addition to nasal laser irradiation
Description: laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months
Study NCT04503317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill exercise
Description: aerobic exercise once per day, 3 times per week for three months
Study NCT04503317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill exercise
Description: aerobic exercise once per day, 3 times per week for three months
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: 600 mg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: 25mg/kg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: 15mg/kg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg QD
Study NCT02256696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 300 mg QD
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
Study NCT03555149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB928
Description: AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
Study NCT03555149 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LOAd703
Description: LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
Study NCT01320397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 6 microgram capsules
Study NCT01320397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 50 micrograms capsules
Study NCT01320397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 500 micrograms capsules
Study NCT01320397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 50 mg once a day
Study NCT01285843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Minimally Invasive Approach (AMIS)
Study NCT00766766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risk and Behavioral Skills Coaching Sessions
Description: Health Risk and Behavioral Skills Coaching Sessions
Study NCT00766766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching Sessions
Description: Telephone Coaching Sessions
Study NCT00766766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Feedback Letter
Description: Physician Feedback Letter
Study NCT02114021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone gel
Description: betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
Study NCT02114021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine jelly
Description: the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
Study NCT02114021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: distilled water
Description: The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
Study NCT03780582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-human interaction
Description: Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
Study NCT04335435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Bran Consumption
Description: Oat bran (120 g), single dose.
Study NCT04781712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular mHealth for Tailored Rehabilitation
Description: an individually tailored self-management through the mHealth app with a smart band worn on the wrist
Study NCT02233530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CST intervention
Description: The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
Study NCT04119687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FX201
Description: FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
Study NCT02142816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Fluid therapy guided by doppler
Study NCT02142816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVI'
Description: Fluid therapy guided by PVI
Study NCT00972270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella LP 2.5
Description: Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
Study NCT00972270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Aortic Balloon Pump
Description: The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
Study NCT05252637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Fascial Posterior Vagina Duplication
Description: Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
Study NCT02202304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/Thymol varnish
Description: This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
Study NCT02202304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine/Thymol varnish
Description: This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
Study NCT03980067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
Study NCT03466632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
Study NCT03466632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
Study NCT00490035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
Study NCT00490035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
Study NCT00490035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
Study NCT00490035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
Study NCT01108939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Study NCT01108939 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Study NCT04870996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
Study NCT04870996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
Study NCT04870996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
Study NCT04870996 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
Study NCT02283879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
Study NCT03804281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group
Description: The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
Study NCT03804281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
Study NCT04261140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQUIA Forte Fil
Description: Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit
Study NCT04261140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clearfil Majesty Esthetic
Description: Apply in 2-mm increment, light cure for 20 s
Study NCT04261140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NexComp Flow
Description: Apply in 2-mm increment light cure for 20 s
Study NCT04261140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3M Espe Bulk-fill
Description: Apply in single increment up to 4 mm; light curing for 20 s
Study NCT04059718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Thrive Peer-Led Online Self-Management Program
Description: 6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
Study NCT01724827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ceramic (Empress CAD, Ivoclar Vivadent)
Description: Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
Study NCT01724827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: composite (Lava Ultimate, 3M Espe)
Description: Nanohybrid composite resin (Lava Ultimate, 3M Espe)
Study NCT00743756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: home-delivered meals
Description: 3 diabetic meals per day, 7 days per week for 12 months
Study NCT00743756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: home-delivered meals
Description: diabetic meals 3 times per day, 7 days a week for six months
Study NCT00743756 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: diabetes education for 12 months
Description: subjects in this group received diabetes education for 12 months
Study NCT01447888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150% Oral Morphine Equivalent (OME)
Description: Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
Study NCT01447888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Judgment
Description: This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
Study NCT02414698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Hydrodiscectomy
Description: The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
Study NCT02414698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TESI
Description: Transforaminal epidural steroid injections given in the lumbar spine.
Study NCT01449565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 3 monthly intramuscular injections of naltrexone 380 mg (extended release)
Study NCT01449565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
Study NCT02783898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor Heart Monitor
Description: Smart phone based ECG event recorder
Study NCT02391337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Drug intervention
Study NCT02391337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Drug intervention
Study NCT00435617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Mentor
Description: Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
Study NCT00465517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Oral suspension 200-500 mg 3x/day
Study NCT00465517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active placebo